| Bolt Biotherapeutics is a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. Co. develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Co.'s preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. We show 2 historical shares outstanding datapoints in our coverage of BOLT's shares outstanding history.|
Understanding the changing numbers of BOLT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BOLT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BOLT by allowing them to research BOLT shares outstanding history
as well as any other stock in our coverage universe.